(Q50027697)

English

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

scientific article published on 16 January 2018

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. (English)

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

1 reference

based on heuristic

inferred from title

29

object named as

Marc Ladanyi

1 reference

Europe PubMed Central

23 February 2018

Nikolaus Schultz

31

object named as

Nikolaus Schultz

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Kurt A Schalper

12

object named as

Kurt A Schalper

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Jedd D. Wolchok

18

object named as

Jedd Wolchok

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

3

object named as

Konnor La

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

author name string

Hira Rizvi

1

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Francisco Sanchez-Vega

2

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Walid Chatila

4

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Philip Jonsson

5

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Darragh Halpenny

6

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Andrew Plodkowski

7

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Niamh Long

8

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Jennifer L Sauter

9

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Natasha Rekhtman

10

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Travis Hollmann

11

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Justin F Gainor

13

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Ronglai Shen

14

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Ai Ni

15

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Kathryn C Arbour

16

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Taha Merghoub

17

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Alexandra Snyder

19

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Jamie E Chaft

20

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Mark G Kris

21

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Charles M Rudin

22

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Nicholas D Socci

23

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Michael F Berger

24

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Barry S Taylor

25

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Ahmet Zehir

26

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

David B Solit

27

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Maria E Arcila

28

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Gregory J Riely

30

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Matthew D Hellmann

32

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

language of work or name

0 references

publication date

16 January 2018

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Journal of Clinical Oncology

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

JCO2017753384

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

PD-1 blockade induces responses by inhibiting adaptive immune resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Genetic basis for clinical response to CTLA-4 blockade in melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

Genomic landscape of non-small cell lung cancer in smokers and never-smokers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

ContEst: estimating cross-contamination of human samples in next-generation sequencing data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6075848

26 August 2018

OncoKB: A Precision Oncology Knowledge Base

1 reference

https://pubmed.ncbi.nlm.nih.gov/29337640

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2017.75.3384

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

0 references

1 reference

Europe PubMed Central

23 February 2018

http://europepmc.org/abstract/MED/29337640

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50027697&oldid=1719227756"